Havedic Pharmaceutical announces the hiring of Yuriy Pomeshchik MD, PhD as Director of In Vitro. Before joining Havedic, Yuriy held a position as Associate Researcher

Havedic Pharmaceutical is pleased to share the news on our participation in this year’s  #ASGCT2024, and the symposium held by Myrtelle, Inc., where we will

Havedic Pharmaceutical is excited to announce a new partnership with Prevail Pharmaceutical to develop novel adeno-associated virus (AAV) capsids for disorders of the nervous system. (link)

Havedic Pharmaceutical has hired Magnus Henriks as the Chief Executive Officer. Prior to joining Havedic, Magnus has had leading positions in various commercial companies. 

Havedic Pharmaceutical has gone into an agreement, for a continuous partnership with Myrtelle, Inc. In the new collaboration Havedic will validate a defined number of

Lena Mårtensson has been assigned to the Havedic Pharmaceutical Board of Directors. Lena has an extensive background within Life Science, with multiple project and business

Havedic Pharmaceutical will participate in the Viral Vector Formulation Process & Development Summit in Amsterdam 11-13 June. Our CSO, Patrick Aldrin-Kirk, will present the Havedic

Havedic Pharmaceutical is pleased to announce a new joint Photochemical Lysis project with PCI Biotech. In the project, Havedic will develop and produce AAV, as

Havedic Pharmaceutical hires Patrick Aldrin-Kirk, PhD as its new Chief Scientific Officer. Before joining Havedic, Patrick did his postdoc and held a position as Associate